<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Staphylococcal toxic shock syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Staphylococcal toxic shock syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Staphylococcal toxic shock syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vivian H Chu, MD, MHS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandra Nelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staphylococcal toxic shock syndrome (TSS) is a clinical illness characterized by rapid onset of fever, rash, hypotension, and multiorgan system involvement. TSS due to
         <em>
          Staphylococcus aureus
         </em>
         was initially described in 1978; the disease came to public attention in 1980 with the occurrence of a series of menstrual-associated cases [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of staphylococcal TSS will be reviewed here. Other issues related to staphylococcal infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">
          "Clinical manifestations of Staphylococcus aureus infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults"
         </a>
         .)
        </p>
        <p>
         TSS due to streptococcal species is also discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">
          "Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">
          "Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         TSS associated with
         <em>
          S. aureus
         </em>
         was first described in a series of pediatric cases in 1978 [
         <a href="#rid1">
          1,3
         </a>
         ]. The incidence rose sharply in 1980; more than 800 cases of menses-related TSS occurred, largely among young women [
         <a href="#rid2">
          2,4
         </a>
         ]. Clinical illness arose during menstruation and was associated with use of absorbent tampons [
         <a href="#rid3">
          3,5
         </a>
         ]. The incidence of TSS declined sharply after the withdrawal of some tampon brands.
        </p>
        <p>
         Subsequently, between 2000 and 2003, the incidence rose slightly; in one report, the incidence increased from 0.8 to 3.4 per 100,000 [
         <a href="#rid6">
          6
         </a>
         ]. These cases occurred among women of menstrual age but included both menstrual and nonmenstrual cases. The observed increase in the number of cases may reflect increased recognition due to active laboratory testing for toxin-producing strains, rather than an overall increase in incidence. One study in Minneapolis between 2000 and 2006 noted a stable incidence of staphylococcal TSS overall, with decreasing annual incidence of menstrual TSS among women &gt;24 years [
         <a href="#rid7">
          7
         </a>
         ]. A review of patients with TSS in Colorado demonstrated no significant change in the incidence of staphylococcal TSS between 1993 and 2006 [
         <a href="#rid8">
          8
         </a>
         ]. A survey of TSS cases in the United Kingdom from 2008 to 2012 noted a stable incidence of nonmenstrual TSS but a decline in menstrual TSS cases; in this study, 59 percent of cases were nonmenstrual [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Menstrual cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Between 1979 and 1996, approximately 5300 cases of staphylococcal TSS were reported [
         <a href="#rid10">
          10
         </a>
         ]. The proportion of cases associated with menstruation decreased significantly between 1979 and 1996 (from 91 percent between 1979 and 1980, to 59 percent between 1987 and 1996).
        </p>
        <p>
         Between 1980 and 1986, the number of cases of menstrual TSS declined (from 9 in 100,000 to 1 in 100,000 women) [
         <a href="#rid11">
          11
         </a>
         ]. Between 1979 and 1996, the case-fatality rate for menstrual TSS also declined (from 5.5 percent between 1979 and 1980, to 1.8 percent between 1987 and 1996) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The decrease in cases of menstrual TSS may be explained in part by the withdrawal of highly absorbent tampons and polyacrylate rayon-containing products from the market; however, tampon use remains a risk factor for TSS [
         <a href="#rid12">
          12
         </a>
         ]. Women who develop TSS are more likely to have used tampons with high absorbency, used tampons continuously for more days of their cycle, and kept a single tampon in place for a longer period of time [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Nonmenstrual cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least half of reported staphylococcal TSS cases are not related to menstruation [
         <a href="#rid11">
          11,15
         </a>
         ]. Nonmenstrual TSS can occur in a variety of clinical circumstances, including surgical and postpartum wound infections, mastitis, septorhinoplasty, sinusitis, osteomyelitis, arthritis, burns, cutaneous and subcutaneous lesions (especially of the extremities, perianal area, and axillae), respiratory infections following influenza, and enterocolitis [
         <a href="#rid16">
          16-24
         </a>
         ].
        </p>
        <p>
         In one report including 5300 cases of TSS between 1979 and 1996, the proportion of TSS cases following surgical procedures increased from 14 percent to 27 percent [
         <a href="#rid10">
          10
         </a>
         ]. In this report, 93 percent of cases occurred among women, and 73 percent of nonmenstrual cases occurred among women [
         <a href="#rid10">
          10
         </a>
         ]. The case-fatality rate for nonmenstrual TSS was 5 percent.
        </p>
        <p>
         In another study including 130 TSS cases, the gender distribution was equal (with exclusion of vaginal and postpartum-associated cases) [
         <a href="#rid25">
          25
         </a>
         ]. A subsequent report including 61 TSS cases between 2000 and 2006 noted nonmenstrual TSS comprised 46 percent of cases; among these, no primary source was identified in 36 percent of cases [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Compared with patients with menstrual TSS, patients with nonmenstrual TSS are older (mean age 27 versus 23 years) [
         <a href="#rid15">
          15,21,25
         </a>
         ].
        </p>
        <p>
         TSS also occurs in children. In the United States between 1979 and 1996, children &lt;2 years accounted for approximately half of pediatric cases; antecedent cutaneous lesions were present in 62 percent of cases [
         <a href="#rid10">
          10
         </a>
         ]. Similarly, in the United Kingdom between 2008 and 2012, children ≤16 years accounted for 39 percent of all cases; 42 percent of pediatric cases occurred in children &lt;2 years [
         <a href="#rid9">
          9
         </a>
         ]. A subsequent report from 2009 to 2014 estimated that among more than 8200 children with septic shock (the median age 14 years; 69 percent female), 9 percent were thought to have staphylococcal TSS [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          MICROBIOLOGY AND PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H1557199379">
         <span class="h2">
          S. aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most reported cases of TSS have been due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA). As an example, a multicenter study in France from 2005 to 2020 found that 92 (96 percent) of 96 critically ill individuals with menstrual TSS grew MSSA from the vagina [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         However, as rates of infection due to methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) have increased, cases of TSS due to MRSA have also emerged [
         <a href="#rid28">
          28,29
         </a>
         ]. MRSA strains are capable of producing TSS toxin-1 (TSST-1) and other exotoxins, and patients infected with these strains may develop TSS.
        </p>
        <p>
         In one series including 30 patients from France and Switzerland with infection due to TSST-1-positive MRSA strains, 5 had TSS, 9 had possible TSS (fever and rash without shock), 2 had neonatal TSS-like exanthematous disease (NTED), 1 had scarlet fever, and the others had other infections [
         <a href="#rid28">
          28
         </a>
         ]. The MRSA strains were community acquired (CA) in approximately 30 percent of cases. NTED has also been reported in neonates in Japan and France who are colonized with TSST-1-producing MRSA [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89273.html" rel="external">
          "Erythroderma in children", section on 'Neonatal toxic shock syndrome-like exanthematous disease'
         </a>
         .)
        </p>
        <p>
         In another series of CA-MRSA isolates derived from a Native American reservation, a high prevalence of superantigens (ie, SEB or SEC) was observed; these isolates were genetically related to nonmenstrual TSS-causing strains from elsewhere in the United States [
         <a href="#rid29">
          29
         </a>
         ]. The potential for CA-MRSA strains to cause TSS was also demonstrated in a series of cases in Japan where TSS was due to CA-MRSA isolates producing TSST-1, SEB, SEC, or other exotoxins [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1106547416">
         <span class="h2">
          Toxin production
         </span>
         <span class="headingEndMark">
          —
         </span>
         Toxin production plays in important role in the pathogenesis of staphylococcal TSS [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         TSST-1 was the initial exotoxin isolated from
         <em>
          S. aureus
         </em>
         isolates implicated in TSS [
         <a href="#rid34">
          34,35
         </a>
         ]. TSST-1 is produced by 85 to 100 percent of
         <em>
          S. aureus
         </em>
         strains associated with menstrual cases of TSS and by 40 to 60 percent of strains associated with nonmenstrual cases [
         <a href="#rid27">
          27
         </a>
         ]. The reason for the discrepancy in TSST-1 production between menstrual and nonmenstrual cases is not well understood [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Other toxins may be more virulent than TSST-1; in one study of 32
         <em>
          S. aureus
         </em>
         isolates from nonmenstrual TSS, 50 percent of individuals infected with a TSST-1-negative strain died, compared with 10 percent of TSST-1-positive strains [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Other potential toxins include enterotoxins A, B, C, D, E, and H. Several animal studies suggest that enterotoxin A may be a cofactor of TSST-1 [
         <a href="#rid38">
          38,39
         </a>
         ]. Staphylococcal enterotoxin B is produced by 38 to 62 percent of nonmenstrual TSST-1-negative strains [
         <a href="#rid40">
          40,41
         </a>
         ]. In a study of 183 isolates of
         <em>
          S. aureus
         </em>
         from clinical specimens (but not necessarily TSS cases), 40 percent of the strains produced one or more toxins [
         <a href="#rid42">
          42
         </a>
         ]. TSST-1 was produced by 14 percent of isolates; enterotoxins A, B, C, and D were produced by 20, 8, 6, and 3 percent of isolates, respectively.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Role of superantigens
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          S. aureus
         </em>
         exotoxins are superantigens capable of activating large numbers of T cells, resulting in massive cytokine production [
         <a href="#rid43">
          43
         </a>
         ]. In typical T cell recognition, an antigen is taken up by an antigen-presenting cell, processed, expressed on the cell surface in complex with class II major histocompatibility complex (MHC), and recognized by an antigen-specific T cell receptor. Superantigens do not require processing by antigen-presenting cells; they interact directly with the invariant region of the class II MHC molecule. Two regions of the TSST-1 toxin have been found to be important for MHC class II binding [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3987.html" rel="external">
          "Human leukocyte antigens (HLA): A roadmap", section on 'Class II region'
         </a>
         .)
        </p>
        <p>
         Activated T cells release interleukin (IL)-1, IL-2, tumor necrosis factor (TNF)-alpha, TNF-beta, and interferon (IFN)-gamma in large amounts. IL-1 is an endogenous pyrogen and thus causes high fevers. In addition, IL-1 mediates skeletal muscle proteolysis and probably accounts for the myalgia and elevated creatine phosphokinase seen in TSS [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2734.html" rel="external">
          "Pathophysiology and treatment of fever in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5989.html" rel="external">
          "Fever in infants and children: Pathophysiology and management", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         TNF production inhibits polymorphonuclear leukocyte (PMN) functions. TSST-1-producing
         <em>
          S. aureus
         </em>
         do not engender a purulent response, which in part may be explained by PMN inhibition [
         <a href="#rid43">
          43
         </a>
         ]. In addition, data suggest that TSST-1 and enterotoxin B repress production of other
         <em>
          S. aureus
         </em>
         exoproteins, which may explain the absence of purulence in
         <em>
          S. aureus
         </em>
         infections associated with TSS [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Dermatologic manifestations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Host immune response
         </span>
         <span class="headingEndMark">
          —
         </span>
         The host immune response to
         <em>
          S. aureus
         </em>
         exotoxins plays an important role in the pathogenesis of TSS. Approximately 70 to 80 percent of individuals develop antibody to TSST-1 by early adulthood; by the fourth decade, such antibody is present in 90 to 95 percent of individuals [
         <a href="#rid47">
          47,48
         </a>
         ]. In one study including more than 3000 menstruating women in North America, TSST-1 antibody titers among Black women were lower than among White women (89 versus 98 percent) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         The age of six months to two years is a period of vulnerability during which passive immunity is waning but active immunity has not developed. In one study, detectable antibody titers to TSST-1 among infants age 0 to 6 months were observed in 76 percent of cases; among children 7 to 24 months of age, detectable antibodies were observed in 30 percent of cases [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Patients with TSS do not develop a sufficient antibody response to TSST-1; in addition, they frequently fail to develop appropriate antibodies in convalescent serum [
         <a href="#rid50">
          50
         </a>
         ]. Reduced titers to other staphylococcal enterotoxins in patients with TSS have also been observed [
         <a href="#rid34">
          34
         </a>
         ]. In one study of burn patients with MRSA infection, TSST-1 antibody level was lower among patients who developed TSS than those who did not [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3749288091">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The symptoms and signs of TSS develop rapidly (within 48 hours), frequently in otherwise healthy individuals [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Clinical manifestations of staphylococcal TSS include fever/chills, hypotension (may include orthostasis or syncope), dermatologic manifestations (diffuse macular erythroderma, followed by desquamation one to two weeks later), and multiorgan system involvement [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         Manifestations of multiorgan system involvement include gastrointestinal symptoms (abdominal pain, vomiting, and/or watery diarrhea), myalgias, mucous membrane (vaginal, oropharyngeal, or conjunctival) involvement, renal involvement, hepatic involvement, thrombocytopenia, and neurologic symptoms (headache, somnolence, confusion, irritability, agitation, hallucinations).
        </p>
        <p>
         The clinical presentations of menstrual and nonmenstrual TSS are similar. In one small study, nonmenstrual TSS was associated with earlier onset of rash and fever, more pronounced renal and central nervous system (CNS) complications, and less musculoskeletal involvement [
         <a href="#rid54">
          54
         </a>
         ]. In menstrual cases, the median interval between the onset of menstruation and TSS is two to three days [
         <a href="#rid55">
          55
         </a>
         ]. In postsurgical infection, the median interval between surgery and TSS is two days; however, onset of TSS has been reported as late as 65 days postoperatively [
         <a href="#rid16">
          16,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3918418297">
         <span class="h3">
          Systemic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic findings for TSS are nonspecific but are usually consistent with sepsis. Fever is typically ≥38.9°C (102.0°F).
        </p>
        <p>
         Leukocytosis may be absent, but the total number of mature and immature neutrophils usually exceeds 90 percent (immature neutrophils may account for 25 to 50 percent of the total number of neutrophils).
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid onset of hypotension (for adults: systolic blood pressure ≤90 mmHg; for children &lt;16 years of age: less than fifth percentile by age) is a hallmark of TSS and may be unresponsive to large quantities of intravenous fluids. Cyanosis of the extremities may be evident on examination. Hypotension often leads to tissue ischemia and organ failure.
        </p>
        <p>
         The hypotension is caused by toxin-induced cytokine release which decreases systemic vascular resistance and causes leakage of fluid from the intravascular to the interstitial space [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Dermatologic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of skin manifestations are seen in TSS.
        </p>
        <p>
         The initial erythroderma is characterized by a diffuse, red, macular rash resembling sunburn that also involves the palms and soles  (
         <a class="graphic graphic_picture graphicRef77600" href="/z/d/graphic/77600.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef82561" href="/z/d/graphic/82561.html" rel="external">
          picture 2
         </a>
         ). This rash can be subtle and fleeting. In postoperative TSS, the erythema may be more intense around the surgical wound site. Surgical wounds (and other cutaneous sites of infection) that harbor toxin-producing
         <em>
          S. aureus
         </em>
         frequently appear benign, without obvious purulence [
         <a href="#rid25">
          25,54
         </a>
         ].
        </p>
        <p>
         Mucosal involvement includes conjunctival-scleral hemorrhage  (
         <a class="graphic graphic_picture graphicRef66457" href="/z/d/graphic/66457.html" rel="external">
          picture 3
         </a>
         ) and hyperemia of the vaginal and oropharyngeal mucosa [
         <a href="#rid57">
          57
         </a>
         ]. In more severe cases, superficial ulcerations occur on the mucous membranes, and petechiae, vesicles, and bullae develop.
        </p>
        <p>
         Patients may also have nonpitting edema due to increases in interstitial fluid.
        </p>
        <p>
         Late-onset skin manifestations include a pruritic maculopapular rash (may occur one to two weeks after onset of illness) and desquamation of the palms and soles (characteristically begins one to three weeks after onset of illness)  (
         <a class="graphic graphic_picture graphicRef59735" href="/z/d/graphic/59735.html" rel="external">
          picture 4
         </a>
         ). In some cases, TSS may not be considered in the differential diagnosis until desquamation is observed; this is particularly true in nonmenstrual disease [
         <a href="#rid58">
          58
         </a>
         ]. Some patients also experience loss of hair and nails one to two months following onset of illness.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Multiorgan system involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         TSS can involve any organ system, and laboratory findings typically reflect organ failure due to shock:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal (GI)
         </strong>
         – GI symptoms are common and include abdominal pain, vomiting, and/or profuse watery diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Muscular
         </strong>
         – Many patients report diffuse myalgias and weakness. These symptoms are often accompanied by an increase in serum concentrations of creatine phosphokinase (CPK).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal
         </strong>
         – Blood urea nitrogen (BUN) and creatinine are often elevated due to prerenal or intrinsic renal failure, and are often accompanied by other metabolic abnormalities including hyponatremia, hypoalbuminemia, hypocalcemia, and hypophosphatemia [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic
         </strong>
         – Elevated liver function tests (eg, transaminases and/or bilirubin) often occur and are indicative of hepatic involvement [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic
         </strong>
         – Thrombocytopenia and anemia are often present during the first few days, frequently accompanied by prolonged prothrombin (PT) and partial thromboplastin times (PTT). Disseminated intravascular coagulation (DIC) may be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system
         </strong>
         – Neurologic findings, such as disorientation, confusion, somnolence, or seizures, can occur [
         <a href="#rid62">
          62
         </a>
         ]. Other CNS findings have been reported as well, including headache, irritability, agitation, and hallucinations. Cerebral edema may be evident on imaging in patients with CNS symptoms, especially if such symptoms occur in the absence of fever and hypotension [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other organ systems
         </strong>
         – Pulmonary edema and pleural effusions can occur. Cardiomyopathy has also been reported [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There is also a variant of TSS described in patients with AIDS; this presentation is characterized by a subacute illness with persistent and recalcitrant erythroderma, desquamation, mucosal injection, fever, and hypotension lasting or recurring over a period of weeks [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staphylococcal TSS should be suspected in otherwise healthy individuals with rapid onset of fever, rash, hypotension, and multiorgan system involvement; relevant risk factors include recent tampon use (in females), recent surgery, and recent infection (involving skin or soft tissue or other site).
        </p>
        <p>
         Detection of
         <em>
          S. aureus
         </em>
         in culture is
         <strong>
          not
         </strong>
         required for the diagnosis of staphylococcal TSS since cultures are not always positive. The diagnosis is based solely on clinical manifestations coupled with laboratory abnormalities that suggest organ dysfunction in the absence of alternative etiologies. Examination for foreign bodies, including tampons if appropriate, should be performed and any potentially infected foreign body should be removed. Details regarding clinical manifestations and laboratory findings are found above. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         Cultures should be obtained from blood, mucosal sites (including the vagina in cases of suspected menstrual TSS), wounds, and nares.
         <em>
          S. aureus
         </em>
         is recovered from blood cultures in approximately 5 percent of cases [
         <a href="#rid25">
          25
         </a>
         ]. Involved wound or mucosal sites may grow
         <em>
          S. aureus
         </em>
         in 80 to 90 percent of cases [
         <a href="#rid27">
          27,66
         </a>
         ].
        </p>
        <p>
         In settings where further laboratory investigation is feasible, additional tests can be helpful in making a retrospective diagnosis of TSS.
         <em>
          S. aureus
         </em>
         isolates can be tested for toxin production in research laboratories. In addition, acute and convalescent serum can be analyzed for antibody responses to various
         <em>
          S. aureus
         </em>
         exotoxins. The presence of a strain of
         <em>
          S. aureus
         </em>
         that produces toxin in a patient who does not have acute-phase antibody to the toxin is highly suggestive of TSS.
        </p>
        <p class="headingAnchor" id="H697201191">
         <span class="h2">
          Case definition
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention (CDC) has developed a case definition for staphylococcal TSS. This case definition was created by CDC for epidemiologic surveillance and should
         <strong>
          not
         </strong>
         be used clinically to rule out TSS in patients who are highly suspected of having the illness.
        </p>
        <p>
         According to the CDC case definition, a confirmed case is a case that meets the following clinical criteria  (
         <a class="graphic graphic_table graphicRef54778" href="/z/d/graphic/54778.html" rel="external">
          table 1
         </a>
         ): fever, hypotension, diffuse erythroderma, desquamation (unless the patient dies before desquamation can occur), and involvement of at least three organ systems, with cultures negative for alternative pathogens and serologic tests negative for other conditions (if obtained). A patient who is missing one of the above clinical criteria may be considered a probable case.
        </p>
        <p>
         Not all patients with staphylococcal TSS meet the CDC's case definition. For example, in a multicenter study in France from 2005 to 2020, only 53 (52 percent) of 102 critically ill patients with menstrual TSS met the CDC's case definition for probable TSS and none met the definition for confirmed TSS [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of staphylococcal TSS includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Streptococcal TSS – Streptococcal TSS typically presents with pain that precedes physical findings of infection. At the site of minor trauma (such as a bruise, strained muscle, or sprained ankle), patients may develop deep infection such as necrotizing fasciitis or myonecrosis, often with no visible break in the skin. The diagnosis of streptococcal TSS consists of hypotension and isolation of streptococci from a normally sterile site, together with two or more findings including renal dysfunction, coagulopathy, liver dysfunction, acute respiratory distress syndrome, rash, and/or soft tissue necrosis. (See
         <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">
          "Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sepsis or septic shock due to other pathogens – Other causes of sepsis include gram-negative and fungal pathogens; in some cases, no organism is identified. Sepsis due to other causes is not classically associated with dermatologic manifestations. The diagnosis is often made empirically at the bedside upon presentation. (See
         <a class="medical medical_review" href="/z/d/html/1657.html" rel="external">
          "Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug reaction – Drug reactions may be associated with fever, systemic symptoms, dermatologic involvement, and neutropenia. The diagnosis should be suspected in a patient presenting with these findings who received a new drug in the previous two to six weeks. The diagnosis is based on history and clinical manifestations. Eosinophilia can further support the diagnosis of a drug reaction. (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kawasaki disease – Kawasaki is a vasculitis that occurs in children, characterized by systemic inflammation manifested by fever and mucocutaneous involvement. The diagnosis is established based on clinical history and supported by laboratory findings. (See
         <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">
          "Kawasaki disease: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         COVID-19 multisystem inflammatory syndrome – There have been reports of multisystem inflammatory syndrome possibly associated with COVID-19 with clinical features similar to those of TSS, Kawasaki disease shock syndrome, and/or Kawasaki disease (eg, abdominal pain, gastrointestinal symptoms, myocarditis), and laboratory findings associated with increased inflammation (eg, elevated C-reactive protein, erythrocyte sedimentation rate, and ferritin). Some, though not all, of these patients have tested positive for SARS-CoV-2. (See
         <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meningococcal infection – Meningococcal infection is characterized by acute onset of fever, nausea, vomiting, headache, confusion, and myalgia. Nonblanching purpuric rash may be observed. The infection is transmitted by person-to-person contact and occurs worldwide. The incubation period is 2 to 10 days, and the diagnosis is established via culture of blood or spinal fluid, agglutination tests, or polymerase chain reaction. (See
         <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">
          "Clinical manifestations of meningococcal infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rocky Mountain spotted fever (RMSF) – RMSF is a tick-borne illness; manifestations include fever, headache, and rash. Typically the rash is petechial, involves the extremities first, and occurs an average of three days after the development of fever. The diagnosis of RMSF can rarely be confirmed or disproved in its early phase. In later illness, the diagnosis can be made by skin biopsy and confirmed serologically. (See
         <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">
          "Clinical manifestations and diagnosis of Rocky Mountain spotted fever"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leptospirosis – Leptospirosis is characterized by fever, rigors, myalgia, conjunctival suffusion, and headache; respiratory involvement can develop as a complication. Less common symptoms and signs include cough, nausea, vomiting, diarrhea, abdominal pain, and jaundice. It is transmitted via exposure to animal urine, contaminated water or soil, or infected animal tissue; outbreaks in endemic areas are associated with increased rainfall or flooding. The incubation is 2 to 29 days. The diagnosis is established via serology or culture of blood or urine (See
         <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">
          "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dengue fever – The cardinal features of dengue fever include fever, increased vascular permeability, hemorrhagic manifestations, and marked thrombocytopenia (≤100,000 cells/mm
         <sup>
          3
         </sup>
         ). The virus is transmitted by
         <em>
          Aedes aegypti
         </em>
         mosquitoes, which have broad epidemiologic distribution; the incubation period is 4 to 7 days (range 3 to 10 days). The diagnosis is established via serologic testing. (See
         <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">
          "Dengue virus infection: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteric fever – Enteric fever refers to both typhoid fever (caused by
         <em>
          Salmonella enterica
         </em>
         serotype Typhi [formerly
         <em>
          Salmonella typhi
         </em>
         ]) and paratyphoid fever (caused by
         <em>
          S. enterica
         </em>
         serotype Paratyphi A, B, and C worldwide; predominantly Paratyphi B in South America). Enteric fever is characterized by abdominal pain, fever, and chills. Classic manifestations include relative bradycardia, pulse-temperature dissociation, and "rose spots" (faint salmon-colored macules on the trunk and abdomen). Hepatosplenomegaly, intestinal bleeding, and perforation may occur, leading to secondary bacteremia and peritonitis. Transmission is fecal-oral; the incubation period is 6 to 30 days. The diagnosis is established via culture. (See
         <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">
          "Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of staphylococcal TSS includes treatment of shock, surgical debridement (if warranted), removal of infected foreign bodies, and antibiotic therapy.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Treatment of shock
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staphylococcal TSS may be associated with intractable hypotension and diffuse capillary leak, requiring extensive fluid replacement to maintain perfusion. Vasopressors may also be required. Issues related to management of shock are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">
          "Shock in children in resource-abundant settings: Initial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Surgical debridement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any focus of infection must be drained. Surgical wounds may not appear to be infected because of diminished inflammatory response; nonetheless, wound exploration (with debridement if warranted) should be pursued for patients with TSS in the setting of recent surgery.
        </p>
        <p class="headingAnchor" id="H1910800541">
         <span class="h2">
          Removal of infected foreign bodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infected foreign bodies can act as an ongoing nidus of infection so they must be removed promptly. Examples include tampons, other intravaginal items such as contraceptive sponges and intrauterine devices, nasal packing, and wound packing or dressings.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H1873722734">
         <span class="h3">
          Antibiotic selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antistaphylococcal antibiotic therapy is needed to eradicate organisms and to prevent recurrence [
         <a href="#rid2">
          2,66
         </a>
         ]. No randomized studies have evaluated antibiotic regimens for treatment of TSS; the approach is based on case series and animal studies.
        </p>
        <p class="headingAnchor" id="H58139402">
         <span class="h4">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For empiric treatment of sepsis of unknown cause that might represent staphylococcal TSS, we favor the following regimen (pending culture results):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         (adults: dosing as summarized in the table  (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         ); children: 60 mg/kg per day intravenous [IV] in four divided doses)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          PLUS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         (adults: 900 mg IV every eight hours; children: 25 to 40 mg/kg IV per day in three divided doses)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          PLUS
         </strong>
         one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A combination drug containing a penicillin plus beta-lactamase inhibitor (adults:
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         4.5 g IV every six hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          Cefepime
         </a>
         (adults: 2 g IV every 8 hours; children: 50 mg/kg/dose every 8 hours up to 2 g per dose)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A carbapenem (adults:
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         1 g IV every 8 hours or
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         1 g IV every 6 to 8 hours; children: meropenem 25 mg/kg/dose every 8 hours or imipenem 15 to 25 mg/kg/dose every 6 hours [maximum 4 g per day])
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2126182621">
         <span class="h4">
          Tailored therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment of TSS due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA), we favor the following regimen:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A first-generation cephalosporin such as
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         (adults: 2 g IV every eight hours; children: 100 to 150 mg/kg/day in three divided doses every 8 hours),
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         (adults: 2 g IV every four hours; children: 150 to 200 mg/kg per 24 hours IV in four divided doses)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          PLUS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         (if susceptible; adults: 900 mg IV every eight hours; children: 25 to 40 mg/kg per day in three divided doses)
        </p>
        <p>
        </p>
        <p>
         For treatment of TSS due to methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA), we favor the following regimen:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         (adults: dosing as summarized in the table  (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         ); children: 60 mg/kg per day IV in four divided doses).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatives for patients unable to tolerate
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         include
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (adults: 8 to 10 mg/kg IV every 24 hours; children: age-dependent, as summarized in Lexicomp) or
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          ceftaroline
         </a>
         (adults: 600 mg IV every 12 hours [every 8 hours if bacteremia is present]; children: 15 mg/kg IV every 8 hours infused over 2 hours). (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          PLUS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         (if susceptible; adults: 900 mg IV every eight hours; children: 30 to 40 mg/kg per day in three divided doses)
        </p>
        <p>
        </p>
        <p>
         Inclusion of
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         for treatment of staphylococcal TSS is based on the ability of this drug to suppress synthesis of bacterial toxins. This issue is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3169.html" rel="external">
          "Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention", section on 'General principles'
         </a>
         .)
        </p>
        <p>
         In the event of resistance to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         (adults: 600 mg orally or IV every 12 hours; children &lt;12 years old: 10 mg/kg every 8 hours; children &gt;12 years old: 10 mg/kg every 12 hours [not to exceed adult dose]) is a reasonable alternative agent. In such cases, linezolid may be used as monotherapy given its antistaphylococcal and antitoxin activity [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p>
         Theoretically,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         (which suppresses protein synthesis and, therefore, toxin synthesis) may be more efficacious than cell wall-active agents (such as beta-lactams and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ) for treatment of staphylococcal TSS, since
         <em>
          S. aureus
         </em>
         produces potent toxins and these bacteriostatic drugs suppress toxin production [
         <a href="#rid69">
          69
         </a>
         ]. This approach contrasts with the approach to treatment of bacteremia caused by organisms not associated with toxin production (for which bactericidal antibiotics are preferred over bacteriostatic antibiotics). As an example, in one case report, TSS was treated successfully with linezolid; in vitro analysis of TSST-1 synthesis supported the superior efficacy of protein synthesis inhibitors over cell wall-active agents [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy for
         <em>
          S. aureus
         </em>
         infection depends on the underlying etiology. Issues related to duration of therapy in the setting of
         <em>
          S. aureus
         </em>
         bacteremia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Completing antibiotic therapy'
         </a>
         .)
        </p>
        <p>
         There are no clinical studies to inform duration of therapy for staphylococcal TSS. In the absence of bacteremia or a distinct focus of infection, we typically treat for 10 to 14 days. Combination therapy with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         , if used in place of clindamycin) should be continued until patients are clinically and hemodynamically stable for at least 48 to 72 hours; thereafter, monotherapy with an antistaphylococcal agent may be administered.
        </p>
        <p>
         It is uncertain whether intravenous therapy is required for the entire duration of antibiotic therapy. Following completion of surgical debridement (if needed) and resolution of systemic signs of infection, it may be reasonable to complete the course of antibiotic therapy with an oral regimen.
        </p>
        <p>
         A reasonable oral regimen for completion of treatment for infection due to MSSA consists of
         <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">
          dicloxacillin
         </a>
         (adults: 500 mg orally every six hours; children: 100 mg/kg/day divided every six hours [maximum 500 mg per dose]) or
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         (adults: 500 mg orally every six hours; children: 75 to 100 mg/kg/day in three divided doses [maximum 4 g per day]).
        </p>
        <p>
         A reasonable oral regimen for completion of treatment for infection due to MRSA consists of
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (adults: 300 to 450 mg orally four times daily; children: 10 to 13 mg/kg per dose orally every 8 hours, not to exceed the maximum adult dose) or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         (adults: 600 mg orally every 12 hours; children &lt;12 years old: 10 mg/kg every 8 hours; children &gt;12 years old: 10 mg/kg every 12 hours [not to exceed adult dose]).
        </p>
        <p>
         For patients with deep-seated infections and/or bacteremia, we favor combination therapy with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and an antistaphylococcal penicillin (eg,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         ),
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , until hemodynamics have stabilized. For bacteremia, the duration of antibiotics (of the antistaphylococcal penicillin, cefazolin, or vancomycin) is outlined elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Completing antibiotic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Adjunctive therapy
         </span>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h3">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, we favor not using intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) for treatment of staphylococcal TSS, given the lack of substantive clinical data to suggest a benefit with IVIG in staphylococcal TSS and the potential for adverse effects. Use of IVIG may be considered in patients with severe staphylococcal TSS who are unresponsive to other therapeutic measures [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p>
         It has been proposed that
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         may be beneficial for patients with staphylococcal TSS in the setting of diminished antibody production to toxin [
         <a href="#rid72">
          72-75
         </a>
         ]. However, there have been no controlled trials of IVIG therapy in staphylococcal TSS; data are limited to case reports and retrospective reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one case report of a 39-year-old man with HIV infection and diffuse erythema of the arms and legs, desquamation (of the arms, hands, feet, and eyebrows), pharyngeal erythema, and a lesion that grew a TSST-1-producing
         <em>
          S. aureus
         </em>
         ,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         (200 mg/kg per day) was administered for five days after failing antibiotic therapy; symptoms subsequently resolved [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of patients with necrotizing fasciitis and shock associated with group A
         <em>
          Streptococcus
         </em>
         or
         <em>
          S. aureus
         </em>
         , adjunctive
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         has no apparent impact in mortality [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H727573496">
         <span class="h1">
          COURSE OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with staphylococcal TSS can have rapidly progressive illness and should be monitored closely during treatment.
        </p>
        <p>
         Hypotension can last for several days despite appropriate antimicrobial therapy. Most laboratory tests normalize 7 to 10 days after onset of illness.
        </p>
        <p>
         Diffuse erythroderma is often transient and resolves relatively promptly. Late-onset skin manifestations, including desquamation or maculopapular rash, appear one to three weeks after onset of illness and do not necessarily indicate ongoing infection  (
         <a class="graphic graphic_picture graphicRef59735" href="/z/d/graphic/59735.html" rel="external">
          picture 4
         </a>
         ). Similarly, hair and nail loss do not imply ongoing infection and typically regrow by six months.
        </p>
        <p>
         Some patients have permanent organ dysfunction, such as renal dysfunction. Additionally, persistent neuropsychologic sequelae have been reported such as headaches, memory loss, and poor concentration [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H348147734">
         <span class="h1">
          RECURRENT INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent TSS tends to occur in patients who have not been treated with appropriate antimicrobial therapy and/or who fail to develop an appropriate antibody response to staphylococcal toxins [
         <a href="#rid21">
          21,58,66
         </a>
         ]. Recurrence can occur days to months after the initial episode. In menstrual TSS, recurrent episodes are generally milder than the initial disease [
         <a href="#rid66">
          66
         </a>
         ]. Recurrent infection is managed in the same manner as initial infections. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          MORTALITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The TSS-related mortality rate in menstrual cases has decreased since the syndrome was first recognized in 1980, from 6 percent in 1987 to below 2 percent [
         <a href="#rid10">
          10,27
         </a>
         ]. The mortality due to nonmenstrual TSS is higher and has remained essentially unchanged at approximately 6 percent [
         <a href="#rid10">
          10,12
         </a>
         ]. The mortality due to TSS in children is 3 to 5 percent [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
         In fatal cases, death usually occurs within the first few days of hospitalization but may occur as late as two weeks after admission. Fatalities have been attributed to refractory cardiac arrhythmias, cardiomyopathy, irreversible respiratory failure, and, rarely, bleeding caused by coagulation defects [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3414726487">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have had tampon-associated TSS should not resume tampon use.
        </p>
        <p>
         For patients with staphylococcal TSS and
         <em>
          S. aureus
         </em>
         nasal carriage, we suggest decolonization as an attempt at prevention; however, the impact of this intervention on the likelihood of a subsequent episode of staphylococcal TSS is uncertain. In addition, decolonization itself may not be effective or durable. (See
         <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Targeted decolonization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3554878409">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">
          "Society guideline links: Skin and soft tissue infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Staphylococcal toxic shock syndrome (TSS) first came to public attention in 1980 with the occurrence of a series of menstrual-associated cases, primarily associated with recent tampon use. However, at least half of reported staphylococcal TSS cases are not related to menstruation. Other relevant risk factors include recent surgery and recent infection (involving skin or soft tissue or other site). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Staphylococcal TSS is a clinical illness characterized by rapid onset of fever, rash, hypotension, and multiorgan system involvement. Dermatologic findings manifest as diffuse macular erythroderma followed by desquamation one to two weeks later. The symptoms and signs of TSS develop rapidly (within 48 hours), frequently in otherwise healthy individuals. Clinical criteria for TSS have been established by the United States Centers for Disease Control and Prevention (CDC), although not all patients with TSS meet these clinical criteria  (
         <a class="graphic graphic_table graphicRef54778" href="/z/d/graphic/54778.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Staphylococcal TSS should be suspected in patients with rapid onset of fever, rash, hypotension, and multiorgan system involvement. The diagnosis of staphylococcal TSS is established based on clinical findings. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Cultures (including blood cultures and cultures from mucosal sites [including the vaginal canal in cases of suspected menstrual TSS], wound sites, and nares) should be obtained. Detection of
         <em>
          Staphylococcus aureus
         </em>
         in culture is
         <strong>
          not
         </strong>
         required for the diagnosis of staphylococcal TSS.
         <em>
          S. aureus
         </em>
         is recovered from blood cultures in approximately 5 percent of cases; it is recovered from wound or mucosal sites in 80 to 90 percent of cases. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical management
         </strong>
         – Management of staphylococcal TSS includes treatment of shock, source control (including surgery, if warranted), and antibiotic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management of shock
         </strong>
         – TSS-associated shock requires prompt management. Issues related to management of shock are discussed separately. (See
         <a class="local">
          'Management'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">
          "Shock in children in resource-abundant settings: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Source control
         </strong>
         – Surgical wounds may not appear to be infected because of diminished inflammatory response; nonetheless, wound exploration (with debridement if warranted) should be pursued for patients with TSS in the setting of recent surgery, and any packing should be removed if present. In addition, any foreign material in the vaginal canal (such as a tampon, contraceptive sponge, or intrauterine device) should be removed if present.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotic therapy
         </strong>
         – We suggest that patients with suspected TSS be treated with combination antibiotic therapy including an antistaphylococcal agent and an antibiotic that suppresses protein synthesis such as
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (rather than antistaphylococcal therapy alone) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given the importance of toxin production in the pathogenesis of staphylococcal TSS. For treatment of staphylococcal TSS, we typically use the following regimens; dosing is summarized above (see
         <a class="local">
          'Toxin production'
         </a>
         above and
         <a class="local">
          'Antibiotic selection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with sepsis of unknown cause that might represent staphylococcal TSS, we favor treatment with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , and either a carbapenem or a combination drug containing a penicillin plus a beta-lactamase inhibitor.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with TSS due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         , we favor treatment with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         plus either
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with TSS due to methicillin-resistant
         <em>
          S. aureus
         </em>
         , we favor treatment with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of intravenous
         </strong>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         – For patients with staphylococcal TSS, we suggest not administering intravenous immune globulin (IVIG) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given the lack of substantive clinical data to suggest a benefit with IVIG in staphylococcal TSS and the potential for adverse effects. Use of IVIG may be considered in patients with severe staphylococcal TSS who are unresponsive to other therapeutic measures. (See
         <a class="local">
          'Intravenous immune globulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of decolonization
         </strong>
         – For patients with staphylococcal TSS, we suggest decolonization as an attempt at prevention (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); however, the impact of this intervention on the likelihood of a subsequent episode of staphylococcal TSS is uncertain. (See
         <a class="local">
          'Prevention'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Targeted decolonization'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978; 2:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980; 303:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reingold AL, Hargrett NT, Shands KN, et al. Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med 1982; 96:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Update: toxic-shock syndrome--United States. MMWR Morb Mortal Wkly Rep 1983; 32:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterholm MT, Davis JP, Gibson RW, et al. Toxic shock syndrome: relation to catamenial products, personal health and hygiene, and sexual practices. Ann Intern Med 1982; 96:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004; 42:2875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeVries AS, Lesher L, Schlievert PM, et al. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS One 2011; 6:e22997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smit MA, Nyquist AC, Todd JK. Infectious shock and toxic shock syndrome diagnoses in hospitals, Colorado, USA. Emerg Infect Dis 2013; 19:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma H, Smith D, Turner CE, et al. Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom. Emerg Infect Dis 2018; 24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjeh RA, Reingold A, Weil A, et al. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis 1999; 5:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Reduced incidence of menstrual toxic-shock syndrome--United States, 1980-1990. MMWR Morb Mortal Wkly Rep 1990; 39:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broome CV. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis 1989; 11 Suppl 1:S14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reingold AL, Broome CV, Gaventa S, Hightower AW. Risk factors for menstrual toxic shock syndrome: results of a multistate case-control study. Rev Infect Dis 1989; 11 Suppl 1:S35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billon A, Gustin MP, Tristan A, et al. Association of characteristics of tampon use with menstrual toxic shock syndrome in France. EClinicalMedicine 2020; 21:100308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaventa S, Reingold AL, Hightower AW, et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 1989; 11 Suppl 1:S28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartlett P, Reingold AL, Graham DR, et al. Toxic shock syndrome associated with surgical wound infections. JAMA 1982; 247:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dann EJ, Weinberger M, Gillis S, et al. Bacterial laryngotracheitis associated with toxic shock syndrome in an adult. Clin Infect Dis 1994; 18:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson MA, Todd JK. Toxic shock syndrome associated with Staphylococcus aureus sinusitis in children. J Infect Dis 1990; 161:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison VA, Oldfield EC 3rd. Postoperative toxic shock syndrome. Arch Surg 1983; 118:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson MP, Hoffman EB, Roux P. Severe disseminated staphylococcal disease associated with osteitis and septic arthritis. J Bone Joint Surg Br 1990; 72:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reingold AL, Hargrett NT, Dan BB, et al. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med 1982; 96:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuzevski VD, van Joost T, Wagenvoort JH, Dey JJ. Cutaneous pathology in toxic shock syndrome. Int J Dermatol 1989; 28:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotler DP, Sandkovsky U, Schlievert PM, Sordillo EM. Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man. Clin Infect Dis 2007; 44:e121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 1987; 257:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reingold AL, Dan BB, Shands KN, Broome CV. Toxic-shock syndrome not associated with menstruation. A review of 54 cases. Lancet 1982; 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaensbauer JT, Birkholz M, Smit MA, et al. Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children. Pediatr Infect Dis J 2018; 37:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contou D, Colin G, Travert B, et al. Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study. Clin Infect Dis 2022; 74:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand G, Bes M, Meugnier H, et al. Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France. J Clin Microbiol 2006; 44:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fey PD, Saïd-Salim B, Rupp ME, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kikuchi K, Takahashi N, Piao C, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J Clin Microbiol 2003; 41:3001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Mee-Marquet N, Lina G, Quentin R, et al. Staphylococcal exanthematous disease in a newborn due to a virulent methicillin-resistant Staphylococcus aureus strain containing the TSST-1 gene in Europe: an alert for neonatologists. J Clin Microbiol 2003; 41:4883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sada R, Fukuda S, Ishimaru H. Toxic shock syndrome due to community-acquired methicillin-resistant Staphylococcus aureus infection: Two case reports and a literature review in Japan. IDCases 2017; 8:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spaulding AR, Salgado-Pabón W, Kohler PL, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 2013; 26:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergdoll MS, Crass BA, Reiser RF, et al. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981; 1:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM, Shands KN, Dan BB, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981; 143:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM, Jablonski LM, Roggiani M, et al. Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun 2000; 68:3630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbe PL, Arko RJ, Reingold AL, et al. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA 1985; 253:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Boer ML, Kum WW, Pang LT, Chow AW. Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 (TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized mouse model of lethal shock. Microb Pathog 1999; 27:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Boer ML, Kum WW, Chow AW. Staphylococcus aureus isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in a tampon-associated vaginal infection model of toxic shock syndrome. Can J Microbiol 1999; 45:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1986; 1:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee VT, Chang AH, Chow AW. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated Staphylococcus aureus isolates. J Infect Dis 1992; 166:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehn N, Schaller E, Wagner H, Krönke M. Frequency of toxic shock syndrome toxin- and enterotoxin-producing clinical isolates of Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1995; 14:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993; 167:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsonnet J. Mediators in the pathogenesis of toxic shock syndrome: overview. Rev Infect Dis 1989; 11 Suppl 1:S263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vojtov N, Ross HF, Novick RP. Global repression of exotoxin synthesis by staphylococcal superantigens. Proc Natl Acad Sci U S A 2002; 99:10102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vergeront JM, Stolz SJ, Crass BA, et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis 1983; 148:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 2005; 43:4628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quan L, Morita R, Kawakami S. Toxic shock syndrome toxin-1 (TSST-1) antibody levels in Japanese children. Burns 2010; 36:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonventre PF, Linnemann C, Weckbach LS, et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 1984; 150:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsushima A, Kuroki Y, Nakajima S, et al. Low Level of TSST-1 Antibody in Burn Patients With Toxic Shock Syndrome Caused by Methicillin-Resistant Staphylococcus aureus. J Burn Care Res 2015; 36:e120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wharton M, Chorba TL, Vogt RL, et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kain KC, Schulzer M, Chow AW. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tofte RW, Williams DN. Toxic shock syndrome. Evidence of a broad clinical spectrum. JAMA 1981; 246:2163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesney PJ. Clinical aspects and spectrum of illness of toxic shock syndrome: overview. Rev Infect Dis 1989; 11 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesney PJ, Davis JP, Purdy WK, et al. Clinical manifestations of toxic shock syndrome. JAMA 1981; 246:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews MM, Parent EM, Barry M, Parsonnet J. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis 2001; 32:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesney RW, Chesney PJ, Davis JP, Segar WE. Renal manifestations of the staphylococcal toxic-shock syndrome. Am J Med 1981; 71:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourley GR, Chesney PJ, Davis JP, Odell GB. Acute cholestasis in patients with toxic- shock syndrome. Gastroenterology 1981; 81:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishak KG, Rogers WA. Cryptogenic acute cholangitis--association with toxic shock syndrome. Am J Clin Pathol 1981; 76:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett JA, Graham DR. Toxic shock syndrome presenting as encephalopathy. J Infect 1986; 12:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith DB, Gulinson J. Fatal cerebral edema complicating toxic shock syndrome. Neurosurgery 1988; 22:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson RD, Stevens DL, Melish ME. Direct effects of purified staphylococcal toxic shock syndrome toxin 1 on myocardial function of isolated rabbit atria. Rev Infect Dis 1989; 11 Suppl 1:S313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cone LA, Woodard DR, Byrd RG, et al. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis 1992; 165:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JP, Osterholm MT, Helms CM, et al. Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis 1982; 145:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diep BA, Equils O, Huang DB, Gladue R. Linezolid effects on bacterial toxin production and host immune response: review of the evidence. Curr Ther Res Clin Exp 2012; 73:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diep BA, Afasizheva A, Le HN, et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 2013; 208:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. J Infect Dis 1984; 149:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Best GK, Scott DF, Kling JM, et al. Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun 1988; 56:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonventre PF, Thompson MR, Adinolfi LE, et al. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun 1988; 56:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13:602.
          </a>
         </li>
         <li class="breakAll">
          Chesney PJ, Davis JP. Toxic shock syndrome. In: Textbook of pediatric infectious diseases, 4th ed, Feigin RD, Cherry JD (Eds), WB Saunders, Philadelphia 1998. p.830.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadri SS, Swihart BJ, Bonne SL, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis 2017; 64:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosene KA, Copass MK, Kastner LS, et al. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 1982; 96:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larkin SM, Williams DN, Osterholm MT, et al. Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases. Ann Intern Med 1982; 96:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paris AL, Herwaldt LA, Blum D, et al. Pathologic findings in twelve fatal cases of toxic shock syndrome. Ann Intern Med 1982; 96:852.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3161 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/82681" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Toxic-shock syndrome associated with phage-group-I Staphylococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7432401" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091960" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Toxic shock syndrome surveillance in the United States, 1980 to 1981.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6410169" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Update: toxic-shock syndrome--United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091973" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Toxic shock syndrome: relation to catamenial products, personal health and hygiene, and sexual practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15184497" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21860665" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24188357" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Infectious shock and toxic shock syndrome diagnoses in hospitals, Colorado, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29350159" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10603216" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Toxic shock syndrome in the United States: surveillance update, 1979 1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113167" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reduced incidence of menstrual toxic-shock syndrome--United States, 1980-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2648537" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Epidemiology of toxic shock syndrome in the United States: overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2928651" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors for menstrual toxic shock syndrome: results of a multistate case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32382713" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association of characteristics of tampon use with menstrual toxic shock syndrome in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2928646" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Active surveillance for toxic shock syndrome in the United States, 1986.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7057535" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Toxic shock syndrome associated with surgical wound infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8011830" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bacterial laryngotracheitis associated with toxic shock syndrome in an adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2324544" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Toxic shock syndrome associated with Staphylococcus aureus sinusitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6860126" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Postoperative toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2298804" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Severe disseminated staphylococcal disease associated with osteitis and septic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091959" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nonmenstrual toxic shock syndrome: a review of 130 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2661452" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cutaneous pathology in toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516392" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Toxic shock-like syndrome associated with staphylococcal enterocolitis in an HIV-infected man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3806893" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6119410" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Toxic-shock syndrome not associated with menstruation. A review of 54 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29601458" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33906228" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16517865" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12499191" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843033" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14532250" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Staphylococcal exanthematous disease in a newborn due to a virulent methicillin-resistant Staphylococcus aureus strain containing the TSST-1 gene in Europe: an alert for neonatologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28491813" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Toxic shock syndrome due to community-acquired methicillin-resistant Staphylococcus aureus infection: Two case reports and a literature review in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23824366" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Staphylococcal and streptococcal superantigen exotoxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6112412" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972418" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10816521" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3981783" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10458917" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 (TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized mouse model of lethal shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10408098" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Staphylococcus aureus isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in a tampon-associated vaginal infection model of toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2871397" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1527429" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated Staphylococcus aureus isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7729452" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Frequency of toxic shock syndrome toxin- and enterotoxin-producing clinical isolates of Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486972" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Role of superantigens in human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10721486" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2648540" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mediators in the pathogenesis of toxic shock syndrome: overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110733" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Global repression of exotoxin synthesis by staphylococcal superantigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6631061" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145118" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20036064" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Toxic shock syndrome toxin-1 (TSST-1) antibody levels in Japanese children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6491377" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25094005" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Low Level of TSST-1 Antibody in Burn Patients With Toxic Shock Syndrome Caused by Methicillin-Resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2122225" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Case definitions for public health surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9148133" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8448283" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7289007" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Toxic shock syndrome. Evidence of a broad clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2522671" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical aspects and spectrum of illness of toxic shock syndrome: overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7253137" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical manifestations of toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11317249" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7282746" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Renal manifestations of the staphylococcal toxic-shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7286571" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Acute cholestasis in patients with toxic- shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7293977" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cryptogenic acute cholangitis--association with toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3722844" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Toxic shock syndrome presenting as encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3362331" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Fatal cerebral edema complicating toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2928649" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Direct effects of purified staphylococcal toxic shock syndrome toxin 1 on myocardial function of isolated rabbit atria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1552193" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7069224" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24648596" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Linezolid effects on bacterial toxin production and host immune response: review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23532096" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6715902" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16447124" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16447124" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3346079" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3257201" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023960" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Passive immunity in prevention and treatment of infectious diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023960" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Passive immunity in prevention and treatment of infectious diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28034881" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091958" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Persistent neuropsychological sequelae of toxic shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777108" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Toxic shock syndrome in children: epidemiology, pathogenesis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091957" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091956" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pathologic findings in twelve fatal cases of toxic shock syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
